There were no significant differences between the sensitivity of established and primary GBM cell lines to FK866, and no significant correlation between FK866 sensitivity and expression of any of the key metabolic enzymes NAMPT, NAPRT, NT5E or QPRT (Table S3). This evidence concerns the gene QPRT and glioblastoma.